Bovis sees spike in annual revenue
Bovis, the FTSE 250 construction, project management, and consulting provider, said it remains on track to deliver a strong increase in revenue in 2012.
Bovis, the FTSE 250 construction, project management, and consulting provider, said it remains on track to deliver a strong increase in revenue in 2012.
The group saw a significant increase in private average sales prices due to an improving mix and expects to legally complete around 2,350 homes during 2012 to date.
Average sales price achieved in the year to date for private reservations expected to legally complete in 2012 is around £190,000 compared ith £180,100 achieved on private legal completions in 2011.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Gross profit margin for 2012 is expected to increase to roughly 22%, reflecting the increasing proportion of homes sold on post-downturn sites, Bovis explained.
The significant increase in operating margin combined with improved capital turn will provide an increase in ROCE to nearly 7.5% for 2012 from 5% in 2011.
"Subject to stable market conditions continuing, the group is confident that it can deliver further growth in revenue with strong increases in profit margins. This profit growth combined with a stable capital base will deliver further strong improvements in ROCE in 2013 and beyond," the group said in a statement.
CJ
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published
-
Will the Autumn Budget impact investment markets?
Keir Starmer has warned the Autumn Budget will be “painful”. Will it impact investment markets and should you tweak your portfolio before 30 October?
By Katie Williams Published